ADA: Hengrui, Innovent’s Incretins Shine In China Obesity Studies

Potential Comparative Advantages?

 
• By Dexter Jie Yan
  
China obesity market
Hengrui and Innovent presented latest clinical results for their respective dual incretin receptor agonists at ADA annual meeting. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia